Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-08-22 00:00:00 ET · period of report 2025-08-21 · accession 0001415889-25-022761 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-08-22 | 2025-08-21 | SPRY | Lowenthal Richard E | Pres AND CEO, Dir, 10% | S - Sale | $14.49 | -50.0K | 1.20M | -4% | -$724.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-21 | S | D | 50,000 | $14.49 | 1,196,494 | I By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 | — | — | (F1) The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025. (F2) The weighted average sale price for the transaction reported was $14.4869 and the range of prices were between $14.31 and $14.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F3) The Reporting Person is trustee of the trust. |